Affimed researchers served as co-authors on an abstract for RO7297089 with scientific collaborators from Genentech, a member of the Roche Group Affimed will host a live teleconference at 8am Eastern to discuss the abstracts and recent corporate developments Heidelberg, Germany, May 15, 2020 ? Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that data from two studies investigating innate cell engagers developed from its fit-for-purpose ROCK® platform have been accepted for e-poster presentations at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held on June 22-24, 2020. Affimed researchers served as authors on abstract #5659 and co-authors on abstract #6987 with scientific collaborators from Genentech, a member of the Roche Group, on the respective abstracts that include the following:
Title: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies Abstract: 5659
|